Table 2.
Univariate and multivariate analysis of predictors of survival
| Variable | Hazard ratio | 95%CI | P value |
| Univariate analysis of predictors of survival | |||
| Age (≤ 65 vs > 65 yr) | 1.085 | 0.772-1.525 | 0.638 |
| Gender (M vs F) | 0.861 | 0.607-1.222 | 0.403 |
| Previous treatment (no vs yes) | 1.258 | 0.911-1.738 | 0.164 |
| HCV antibody (negative vs positive) | 0.951 | 0.673-1.344 | 0.776 |
| Stage (I, II, III vs IV) | 2.705 | 1.919-3.814 | < 0.001 |
| Child Pugh classification (A vs B or C) | 1.584 | 1.149-2.184 | 0.005 |
| JIS score (0-2 vs 3-5) | 2.285 | 1.638-3.189 | < 0.001 |
| Total bilirubin (≤ 1.5 mg/dL vs > 1.5 mg/dL) | 1.578 | 1.044-2.385 | 0.031 |
| Albumin (> 3.5 mg/dL vs ≤ 3.5 mg/dL) | 1.527 | 1.100-2.119 | 0.012 |
| Number of tumors (< 10 vs ≥ 10) | 1.920 | 1.378-2.675 | < 0.001 |
| Maximum tumor size (≤ 50 mm vs > 50 mm) | 2.052 | 1.404-2.998 | < 0.001 |
| PVTT grade (Vp0, 1, 2 vs Vp3) | 4.142 | 2.754-6.230 | < 0.001 |
| Tumor distribution (Unilateral vs Bilateral) | 2.237 | 1.464-3.420 | < 0.001 |
| AFP (≤ 100 ng/mL vs > 100 ng/mL) | 2.131 | 1.539-2.949 | < 0.001 |
| AFP-L3 (≤ 50% vs > 50%) | 1.664 | 0.957-2.894 | 0.071 |
| DCP (≤ 100 mAU/mL vs > 100 mAU/mL) | 2.201 | 1.588-3.051 | < 0.001 |
| Therapeutic effect (CR + PR vs SD + PD) | 3.419 | 2.382-4.909 | < 0.001 |
| Multivariate analysis of predictors of survival | |||
| PVTT grade (Vp0, 1, 2 vs Vp3) | 2.310 | 1.217-4.384 | 0.010 |
| AFP (≤ 100 ng/mL vs > 100 ng/mL) | 1.856 | 1.265-2.724 | 0.002 |
| Therapeutic effect (CR + PR vs SD + PD) | 3.392 | 2.240-5.135 | < 0.001 |
The JIS score is obtained by simply adding both scores for the tumor, lymph node, metastasis (TNM) stage and Child-Turcotte-Pugh stage. HCV: Hepatitis C virus; JIS: Japan integrated staging; PVTT: Portal vein tumor thrombosis; AFP: α-fetoprotein; DCP: Des-γ-carboxy prothrombin; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.